Regeneron Stock: Here’s Why Four Expected FDA Approvals Could Push its 36% Rally Even Higher
Regeneron Pharmaceuticals (REGN) is showing strong performance, nearing its 52-week high, driven by an anticipated four FDA approvals in 2026 and a robust pipeline. The company's recent BLA acceptance for garetosmab for FOP, with striking Phase 3 data, highlights its transition from a two-product company to a diversified late-stage platform. Analysts project continued revenue and EPS growth, with TIKR's valuation model suggesting significant upside, contingent on key pipeline readouts and approvals.
Regeneron Pharmaceuticals, Inc. $REGN is Persistent Asset Partners Ltd's 5th Largest Position
Persistent Asset Partners Ltd significantly increased its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 428.0% during the 3rd quarter, making it their 5th largest holding valued at $3.89 million. Other institutional investors also adjusted their positions, and hedge funds now own 83.31% of the company's stock. Insider selling activities were reported by SVP Jason Pitofsky and Director Bonnie L. Bassler, while the company announced an increased quarterly dividend of $0.94.
Bristol Myers Squibb Company $BMY Position Trimmed by Jupiter Asset Management Ltd.
Jupiter Asset Management Ltd. has reduced its stake in Bristol Myers Squibb (BMY) by 31.7% in the third quarter, now holding shares worth approximately $41.23 million. This comes as BMY faces mixed sentiment, with the FDA accepting a New Drug Application for an iberdomide combination, potentially creating a new revenue stream, while the company also missed quarterly EPS estimates and received downward revisions from Zacks Research on future earnings. Despite this, BMY increased its quarterly dividend to $0.63, offering a 4.2% yield, and maintains a "Hold" consensus rating from analysts with an average price target of $60.19.
Rx Rundown: Danaher, Johnson & Johnson, Bayer and more
This article provides an "Rx Rundown" summarizing significant medical marketing news, deal-making, and industry chatter from the previous week. Key highlights include Danaher's acquisition of Masimo for $9.9 billion, Madrigal Pharmaceuticals' $4.4 billion licensing deal, multiple FDA approvals and rejections, notable funding rounds, and industry news such as Bayer's $7.25 billion Roundup settlement and Johnson & Johnson's expansion and paused clinical trials.
China Universal Asset Management Co. Ltd. Has $12.01 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN
China Universal Asset Management Co. Ltd. reduced its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 13.0% in Q3, now holding 21,359 shares worth $12.01 million. Despite this, Wall Street analysts maintain a "Moderate Buy" consensus, with several firms recently raising their price targets, and the company reported strong Q4 earnings, beating estimates and increasing its quarterly dividend. Other hedge funds made various adjustments to their holdings in REGN.
Compass Wealth Management LLC Invests $2.04 Million in Regeneron Pharmaceuticals, Inc. $REGN
Compass Wealth Management LLC has acquired a new stake of 3,634 shares, valued at $2.04 million, in Regeneron Pharmaceuticals (NASDAQ:REGN) during the third quarter. Other institutional investors have also significantly increased their holdings in the biopharmaceutical company. Analysts currently have an average rating of "Moderate Buy" for REGN with a consensus target price of $793.81.
Is Wall Street Bullish or Bearish on Regeneron Pharmaceuticals Stock?
Regeneron Pharmaceuticals (REGN) has outperformed the broader market and its sector peers, with a 14.1% increase over the past year. Despite a mixed earnings surprise history and a slight decline in operating margin in Q4 2025, analysts maintain a "Strong Buy" consensus rating for REGN, with a mean price target suggesting a 10.9% premium.
Vertex Casgevy Rollout Tests Gene Editing Role In Vertex Earnings Story
Vertex Pharmaceuticals and CRISPR Therapeutics are initiating patient treatments with their gene-editing therapy, Casgevy, approved for sickle cell disease and beta thalassemia. This rollout is critical for Vertex as it aims to diversify beyond its cystic fibrosis focus, with Casgevy expected to contribute to a projected US$500 million in non-CF product revenue for 2026. Investors will closely monitor the real-world adoption, patient access, and payer response to this high-complexity treatment, as these factors will shape Vertex's future earnings and its position in the broader gene-editing market.
Here's What Analysts Are Saying About Regeneron Pharmaceuticals (REGN)
Analysts are providing mixed but generally positive outlooks on Regeneron Pharmaceuticals (REGN). RBC Capital reiterated a Hold rating with a $745 price target, while Guggenheim raised its price target to $975 from $865 with a Buy rating, citing upcoming catalysts like clinical data and FDA decisions. Regeneron is also expanding its immunology portfolio, with new data presentations planned for the upcoming AAAAI Annual Meeting.
Here's What Analysts Are Saying About Regeneron Pharmaceuticals (REGN)
RBC Capital reiterated a Hold rating on Regeneron Pharmaceuticals (REGN) with a $745 price target, while Guggenheim raised its price target to $975 from $865, maintaining a Buy rating. Regeneron is expanding its immunology portfolio and pipeline, with 36 abstracts to be presented at the AAAAI Annual Meeting, including new Dupixent analyses and potential FDA decisions for Eylea HD and cemdisiran. The company focuses on developing therapies for diseases like cancer, eye disorders, and allergic conditions.
Here’s What Analysts Are Saying About Regeneron Pharmaceuticals (REGN)
RBC Capital reiterated a Hold rating on Regeneron Pharmaceuticals (REGN) with a $745.00 price target, while Guggenheim raised its price target to $975 from $865, maintaining a Buy rating. Regeneron is actively expanding its immunology portfolio, with new data presentations and upcoming FDA decisions for key programs. Despite REGN's potential, the article suggests that some AI stocks may offer higher returns and lower risk.
Regeneron Pharmaceuticals Says its FOP Drug Candidate Garetosmab's BLA Gets US FDA Priority Review
Regeneron Pharmaceuticals announced that the U.S. FDA has granted Priority Review to its Biologics License Application (BLA) for garetosmab, a drug candidate for the treatment of Fibrodysplasia Ossificans Progressiva (FOP). This designation speeds up the review process for drugs that offer significant improvements in the safety or effectiveness of treating serious conditions. The company's stock symbol is REGN.
Regeneron Pharmaceuticals Inc. Lowers Position in Alnylam Pharmaceuticals, Inc. $ALNY
Regeneron Pharmaceuticals Inc. significantly reduced its stake in Alnylam Pharmaceuticals, Inc. by 68.7% in the third quarter, selling over 3 million shares. Despite this reduction, Alnylam Pharmaceuticals remains Regeneron's largest holding, constituting 90.6% of its portfolio. The article also details recent insider stock sales, an overview of Alnylam's financial performance, and varied analyst ratings and price targets for the company.
FDA grants priority review for Regeneron’s FOP treatment
The FDA has granted priority review to Regeneron Pharmaceuticals' Biologics License Application for garetosmab, a potential treatment for fibrodysplasia ossificans progressiva (FOP). This ultra-rare genetic disorder causes abnormal bone growth. If approved, garetosmab would be the first treatment to reduce new heterotopic bone lesions in FOP patients, with a target decision date set for August 2026.
Here's What Analysts Are Saying About Regeneron Pharmaceuticals (REGN)
RBC Capital reiterated a Hold rating on Regeneron Pharmaceuticals (REGN) with a $745.00 price target, noting the company's expanding immunology portfolio presentations at a key upcoming medical meeting. Guggenheim lifted its price target to $975 from $865 and maintained a Buy rating, citing upcoming catalysts like fianlimab/Libtayo LAG-3 data and FDA decisions for Eylea HD and cemdisiran. Regeneron, known for developing therapies for various diseases, continues to draw analyst attention for its pipeline developments and market potential.
Ex-Dividend Reminder: ONE Gas, AstraZeneca and Regeneron Pharmaceuticals
ONE Gas, Inc. (OGS), AstraZeneca plc (AZN), and Regeneron Pharmaceuticals, Inc. (REGN) are set to trade ex-dividend on February 20, 2026. Investors should expect a slight dip in their share prices, assuming all other factors remain equal, due to the upcoming dividend payments. The article also provides historical dividend charts and current estimated annual yields for each company.
Summer Road LLC Sells 1,307,811 Shares of Ocular Therapeutix, Inc. $OCUL
Summer Road LLC has reduced its stake in Ocular Therapeutix (NASDAQ:OCUL) by selling 1,307,811 shares, now holding 12,579,657 shares, which represents about 7.23% of the company and 98.3% of the firm's portfolio. Despite a recent positive Phase 3 trial result for its eye drug SOL-1 against Regeneron’s Eylea, the stock plummeted over 20% due to investor skepticism regarding the modest benefit and comparator issues. Analysts generally maintain a "Moderate Buy" rating with a consensus price target of $24.00, despite the company's negative EPS, declining revenue, and recent insider selling.
Skandinaviska Enskilda Banken AB publ Lowers Stock Position in Regeneron Pharmaceuticals, Inc. $REGN
Skandinaviska Enskilda Banken AB publ has reduced its stake in Regeneron Pharmaceuticals, Inc. by 16.4% in the third quarter, now owning 56,974 shares valued at $32.01 million. Other institutional investors have also adjusted their positions in REGN. Several Wall Street analysts have updated their price targets and ratings for Regeneron, with a consensus "Moderate Buy" rating and an average target price of $793.81.
Merit Financial Group LLC Buys 1,397 Shares of Regeneron Pharmaceuticals, Inc. $REGN
Merit Financial Group LLC increased its stake in Regeneron Pharmaceuticals, Inc. by 302.4% during the third quarter, purchasing an additional 1,397 shares. This brings their total holdings to 1,859 shares valued at $1,045,000. Other institutional investors also modified their stakes in the biopharmaceutical company, while analysts offered varied ratings with a consensus "Moderate Buy" and target price of $793.81.
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by CenterBook Partners LP
CenterBook Partners LP increased its holdings in Regeneron Pharmaceuticals (NASDAQ:REGN) by 10.9% in the third quarter, making it their 6th largest position. Regeneron reported strong quarterly earnings, surpassing analyst estimates for EPS and revenue. Analysts currently have a "Moderate Buy" rating on the stock with an average price target of $793.81.
Fifth Third Bancorp Raises Stock Position in Regeneron Pharmaceuticals, Inc. $REGN
Fifth Third Bancorp increased its stake in Regeneron Pharmaceuticals, Inc. by 19.0% during the third quarter, bringing its total holdings to 12,063 shares valued at $6.78 million. Regeneron recently surpassed analyst earnings estimates, reporting $11.44 EPS versus $10.74 expected, and the company has also raised its quarterly dividend. Institutional investors hold a significant 83.31% of the biopharmaceutical company's stock, while insiders have sold shares totaling approximately $2.86 million in the last quarter.
Vanguard Group Inc. Trims Stock Position in Regeneron Pharmaceuticals, Inc. $REGN
Vanguard Group Inc. reduced its stake in Regeneron Pharmaceuticals by 4.0% in Q3, selling 375,779 shares but still holding 9,048,269 shares valued at approximately $5.09 billion. Corporate insiders have also sold shares, totaling $2.86 million, leaving them with a 7.02% ownership. Despite Vanguard's trim, analysts maintain a "Moderate Buy" rating with an average target price of $793.81, and Regeneron recently increased its quarterly dividend.
Shell Asset Management Co. Has $276,000 Holdings in Regeneron Pharmaceuticals, Inc. $REGN
Shell Asset Management Co. significantly reduced its stake in Regeneron Pharmaceuticals by 94.9% in Q3, selling 9,206 shares and retaining 490 shares valued at $276,000. Despite this, other major institutions like Dodge & Cox and Norges Bank increased their holdings, contributing to an institutional ownership of 83.31%. Regeneron also reported strong quarterly earnings, beating expectations, and raised its dividend, leading analysts to issue a consensus "Moderate Buy" rating with a target price of $793.81.
Pallas Capital Advisors LLC Takes $1.32 Million Position in Regeneron Pharmaceuticals, Inc. $REGN
Pallas Capital Advisors LLC has acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), purchasing 2,342 shares valued at approximately $1.32 million in the third quarter. Despite recent insider selling, Regeneron Pharmaceuticals exceeded earnings expectations with $11.44 EPS and $3.88 billion in revenue, and has increased its quarterly dividend to $0.94. The company maintains a "Moderate Buy" consensus rating from analysts.
Truist Notes Operational Investments For Cytokinetics, Incorporated (CYTK) to Support Short-Term Growth
Truist has raised its price target for Cytokinetics (CYTK) to $92 from $84, maintaining a Buy rating, ahead of its Q4 results. This adjustment accounts for the impact of a free drug supply program, the annual WAC price for Myqorzo, and increased operational costs anticipated for 2026. Cytokinetics recently launched MYQORZO (aficamten) in the U.S. for treating obstructive hypertrophic cardiomyopathy (oHCM), marking its entry into the commercial biopharmaceutical stage.
Ocular Therapeutix Eyes FDA Filing After Wet AMD Drug Tops Regeneron’s Eylea in Phase 3 Test
Ocular Therapeutix's drug Axpaxli for wet age-related macular degeneration (AMD) showed superior vision maintenance compared to Regeneron's Eylea in a Phase 3 trial. These positive results suggest a potential FDA filing, offering patients a less frequent injection schedule. Despite the strong clinical data, Ocular's stock initially fell due to investor expectations for an even larger treatment effect difference, though analysts believe the results still support FDA approval.
StockWatch: Nektar’s Rezpeg Sparks a Sweet “Comeback Story”
Nektar Therapeutics saw its stock nearly double after announcing positive Phase IIb data for its lead pipeline candidate, rezpegaldesleukin (rezpeg), in atopic dermatitis (AD). This success follows significant clinical setbacks and layoffs in 2022-2023. The company plans to launch a Phase III trial for rezpeg in AD later this year and recently completed a $460 million public offering to fund its advancement.
Sanofi bids adieu to specialty care chief, promotes Manuela Buxo to assume key post
Sanofi has appointed Manuela Buxo as its new specialty care chief, effective March, following the departure of Brian Foard. Buxo, who previously led the global immunology alliance franchise and drove Dupixent's growth, will now oversee the critical specialty care unit, including the blockbuster drug. This leadership change comes shortly after the ouster of CEO Paul Hudson and the upcoming arrival of new CEO Belén Garijo.
Viking Therapeutics Expands Obesity Pipeline As VK2735 Nears Late Stage Trials
Viking Therapeutics is significantly expanding its obesity drug pipeline as its injectable VK2735 nears late-stage trials and an oral version moves towards Phase 3. The company also plans to file an IND for a new amylin agonist. While Viking (NasdaqCM:VKTX) is currently operating at a net loss, its multi-asset approach in a large market dominated by Eli Lilly and Novo Nordisk could offer diverse treatment options, making future clinical readouts and regulatory milestones critical for investors.
NEOS Investment Management LLC Increases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN
NEOS Investment Management LLC significantly increased its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 50.3% in the third quarter, bringing its total holdings to $27.086 million. Other institutional investors also adjusted their positions in the biopharmaceutical company. Regeneron recently reported strong earnings, beating analyst estimates, and increased its quarterly dividend.
Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial
Ocular Therapeutix's experimental eye drug has shown superiority to Regeneron's Eylea in a late-stage clinical trial. This news suggests a potential new competitive treatment option in the ophthalmology market.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Regeneron Pharmaceuticals (NASDAQ:REGN) has received a consensus "Moderate Buy" recommendation from analysts, with an average 1-year price target of $793.81. The company recently reported strong quarterly earnings, beating expectations, and increased its quarterly dividend. Despite some insider selling, institutional investors hold a significant majority of the stock.
Regeneron (REGN) Downgraded at RBC Capital, Price Target Cut Sharply
RBC Capital has downgraded Regeneron Pharmaceuticals (REGN) and significantly cut its price target. This reflects a more cautious outlook from the investment bank regarding the company's prospects.
Price Over Earnings Overview: Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) stock currently trades at $797.57, reflecting a 0.70% drop today, but a 9.46% surge over the past month and an 18.11% gain over the past year. The article analyzes the company's P/E ratio of 18.89 against the Biotechnology industry's aggregate P/E of 81.58, suggesting potential undervaluation compared to its peers. It emphasizes that while a low P/E can indicate undervaluation, investors should consider it alongside other financial metrics, industry trends, and qualitative factors for comprehensive investment decisions.
Price Over Earnings Overview: Regeneron Pharmaceuticals
Regeneron Pharmaceuticals (NASDAQ: REGN) stock price dropped by 0.70% in the current market session, but has increased by 9.46% over the past month and 18.11% over the past year. The company's P/E ratio of 18.89 is lower than the Biotechnology industry's aggregate P/E of 81.58, which could indicate undervaluation or potentially weaker future performance. Investors are cautioned to use P/E ratios in conjunction with other financial metrics and qualitative factors for comprehensive analysis.
Sanofi Tightens Grip on Ocular Therapeutix with Revised Bid as Pivotal SOL-1 Trial Results Loom
Sanofi has reportedly made a significantly revised bid for Ocular Therapeutix, ahead of the biotech company's crucial Phase 3 SOL-1 trial results. The acquisition could reshape the retinal disease market, with Ocular Therapeutix's AXPAXLI therapy holding the potential to offer superior, less frequent treatment for wet age-related macular degeneration. This aggressive move by Sanofi aims to preempt a valuation surge and re-establish its presence in the ophthalmology sector it previously exited.
Retina’s ‘Sustained’ Moment: Ocular Therapeutix Braces for Game-Changing Phase 3 AXPAXLI Data
Ocular Therapeutix (NASDAQ: OCUL) is on the verge of releasing crucial Phase 3 data for its wet Age-Related Macular Degeneration (AMD) treatment, AXPAXLI. This bioresorbable hydrogel implant aims to provide sustained release of axitinib for up to nine months, potentially ending "injection fatigue" for wet AMD patients. Analysts predict a significant binary event for the stock, with success potentially tripling its valuation and failure leading to a sharp decline.
Assetmark Inc. Reduces Holdings in Regeneron Pharmaceuticals, Inc. $REGN
Assetmark Inc. significantly reduced its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 83.7% in Q3, selling over 106,000 shares. Despite this, Regeneron reported strong quarterly earnings, beating EPS estimates, and increased its quarterly dividend. Analysts maintain a "Moderate Buy" consensus rating for REGN with an average price target of $793.81.
Aberdeen Group plc Sells 52,247 Shares of Regeneron Pharmaceuticals, Inc. $REGN
Aberdeen Group plc reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 25.6% in the third quarter, selling 52,247 shares and retaining 151,503 shares valued at $85.19 million. Other institutional investors also adjusted their positions in REGN, and company insiders sold shares totaling over $1.27 million in recent transactions. Regeneron Pharmaceuticals reported strong quarterly earnings, beating analyst estimates, and announced an increased quarterly dividend.
Regeneron Pharmaceuticals (NASDAQ:REGN) Downgraded by Wall Street Zen to Hold
Regeneron Pharmaceuticals (NASDAQ:REGN) has been downgraded by Wall Street Zen from a "buy" to a "hold" rating, though the consensus among analysts remains a "Moderate Buy" with an average target price of $793.81. The company recently reported strong quarterly earnings, exceeding analyst expectations for both EPS ($11.44 vs. $10.74 est.) and revenue ($3.88 billion vs. $3.76 billion est.). Despite the positive financial performance, insider selling has been noted, with SVP Jason Pitofsky and Director Arthur F. Ryan selling a combined 3,636 shares in the last 90 days.
Is Twist’s Expanded NGS Library Kit Portfolio and Higher 2026 Guidance Altering The Investment Case For Twist Bioscience (TWST)?
Twist Bioscience has launched new next-generation sequencing (NGS) library kits to enhance workflows and raised its 2026 revenue guidance to US$435 million to US$440 million. While the expanded product portfolio and increased guidance support the company's growth narrative, the core investment case still hinges on margin improvement and the company's ability to achieve profitability amidst continued losses. The article suggests investors should consider the execution risks in new markets that could keep Twist unprofitable for longer.
Surrozen Conference: CEO Details Wnt-Fzd4 Eye Disease Bet, 2026 IND Plans for SZN-8141
Surrozen's CEO, Craig Parker, outlined the company's strategy for retinal vascular diseases focusing on Wnt pathway biology and antibody engineering, highlighted by their lead candidate SZN-8141. The company plans a 2026 IND filing, positioning SZN-8141 for diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD) by combining Wnt activation with VEGF inhibition. Surrozen has secured significant financing, including a $175 million PIPE, and maintains a collaboration with Boehringer Ingelheim, alongside a broad intellectual property portfolio.
Solid Biosciences Highlights FDA Path for SGT-003 DMD Study, Shares Early Friedreich’s Ataxia Update
Solid Biosciences (NASDAQ: SLDB) recently presented updates on its gene therapy pipeline, focusing on its Duchenne Muscular Dystrophy (DMD) program, SGT-003, and early progress in Friedreich’s ataxia (FA). The company announced alignment with the FDA for a registration pathway for SGT-003, aiming for accelerated approval, and plans a double-blind, placebo-controlled DMD study outside the U.S. with first pediatric dosing expected within 90 days. Solid Biosciences also shared initial positive anecdotal signals from the first Friedreich's ataxia patient treated with a dual-route administration, with plans to dose more patients and release data later this year.
Caprock Group LLC Takes $1.47 Million Position in Regeneron Pharmaceuticals, Inc. $REGN
Caprock Group LLC has initiated a new position in Regeneron Pharmaceuticals (NASDAQ:REGN), purchasing 2,528 shares valued at approximately $1.47 million in the third quarter. This move comes as Regeneron Pharmaceuticals reported strong quarterly earnings, surpassing analyst estimates, and increased its quarterly dividend. The company also maintains a "Moderate Buy" consensus rating from analysts, with a strong institutional ownership of around 83%.
CRISPR Therapeutics (CRSP) Stock: Why Bad Earnings Sparked a 9% Rally
CRISPR Therapeutics (CRSP) stock unexpectedly rallied 9.2% despite missing Q4 earnings estimates, reporting only $864,000 in revenue. The surge was driven by partner Vertex Pharmaceuticals' optimistic 2026 guidance, projecting over $500 million in non-cystic fibrosis product revenue, largely from increased Casgevy infusions. Casgevy, an FDA-approved gene-editing treatment, saw almost triple the patient initiations in 2025 compared to 2024, with expanding reimbursement coverage in the US, Europe, and the Middle East, signaling strong future revenue potential.
Where is Regeneron Pharmaceuticals (REGN) Headed According to Analysts?
Analysts have provided varied ratings and price targets for Regeneron Pharmaceuticals (REGN). RBC Capital reiterated a Hold rating with a $745 price target, while Guggenheim lifted its price target to $975 with a Buy rating, citing upcoming catalysts. Oppenheimer also increased its price target to $865, maintaining an Outperform rating after the company's Q4 earnings broadly met expectations.
Varma Mutual Pension Insurance Co Increases Stake in Regeneron Pharmaceuticals, Inc. $REGN
Varma Mutual Pension Insurance Co has increased its stake in Regeneron Pharmaceuticals by 9.3%, now owning 19,888 shares valued at approximately $11.18 million. This increase comes as Regeneron reported strong quarterly earnings, beating analyst expectations with an EPS of $11.44 and revenue of $3.88 billion, and also announced an increased quarterly dividend of $0.94. The stock currently holds a "Moderate Buy" consensus rating with an average price target of $793.81.
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Wealthfront Advisers LLC
Wealthfront Advisers LLC significantly increased its holdings in Regeneron Pharmaceuticals Inc. by 28.7% in Q3, now owning 5,940 shares valued at $3.34 million. Regeneron recently surpassed quarterly earnings and revenue expectations, reporting an EPS of $11.44 and revenue of $3.88 billion, and has raised its quarterly dividend. Analysts maintain a "Moderate Buy" rating for the stock, with an average target price near its current trading value.
LSV Asset Management Takes $31.26 Million Position in Regeneron Pharmaceuticals, Inc. $REGN
LSV Asset Management has acquired a new position in Regeneron Pharmaceuticals (NASDAQ:REGN) worth approximately $31.26 million, purchasing 55,600 shares during the third quarter. Other institutional investors have also adjusted their holdings in REGN, with hedge funds and institutional investors collectively owning 83.31% of the company's stock. Insider selling activities were also reported, alongside a recent increase in Regeneron's quarterly dividend and updated analyst price targets.
Cibc World Market Inc. Has $8.85 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN
Cibc World Market Inc. significantly increased its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 232.3% during Q3, now holding 15,733 shares valued at approximately $8.85 million. Insiders have recently sold shares worth roughly $2.86 million, though institutional investors and hedge funds still own a substantial 83.31% of the company. Regeneron beat quarterly earnings and revenue expectations, raised its dividend, and maintains a "Moderate Buy" consensus rating among analysts with an average price target of $793.81.
